Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,635,704 papers from all fields of science
Search
Sign In
Create Free Account
MK-7009
Known as:
MK 7009
, MK7009
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Indoles
vaniprevir
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice.
Takuro Uchida
,
N. Hiraga
,
+11 authors
K. Chayama
Virus research
2016
Corpus ID: 29673679
2015
2015
Liver-to-Plasma Vaniprevir (MK-7009) Concentration Ratios in HCV-Infected Patients
D. Wright
,
L. Caro
,
+8 authors
A. Talal
Antiviral therapy
2015
Corpus ID: 25650311
Background Some drugs that are actively taken up into the liver exhibit greater than dose proportional increases in plasma…
Expand
Highly Cited
2012
Highly Cited
2012
Synthesis of the HCV protease inhibitor Vaniprevir (MK-7009) using ring-closing metathesis strategy.
J. Kong
,
Cheng-yi Chen
,
+6 authors
Michael J Zacuto
The Journal of organic chemistry
2012
Corpus ID: 31768280
A highly efficient synthesis of Vaniprevir (MK-7009) has been accomplished in nine linear steps and 55% overall yield. The key…
Expand
Highly Cited
2012
Highly Cited
2012
Vaniprevir with pegylated interferon alpha‐2a and ribavirin in treatment‐naïve patients with chronic hepatitis C: A randomized phase II study
M. Manns
,
E. Gane
,
+8 authors
Andrew W. Lee
Hepatology
2012
Corpus ID: 5229710
Vaniprevir (MK‐7009) is a macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. The aim of the…
Expand
2011
2011
Synthesis of vaniprevir (MK-7009): lactamization to prepare a 20-membered [corrected] macrocycle.
Z. Song
,
D. Tellers
,
+15 authors
D. Tschaen
The Journal of organic chemistry
2011
Corpus ID: 29555434
Development of a practical synthesis of MK-7009, a 20-membered [corrected] macrocycle, is described. A variety of ring-closing…
Expand
Highly Cited
2011
Highly Cited
2011
Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.
J. Gottwein
,
T. Scheel
,
Tanja B. Jensen
,
Lubna Ghanem
,
J. Bukh
Gastroenterology
2011
Corpus ID: 31258959
BACKGROUND & AIMS The hepatitis C virus (HCV) genotype influences efficacy of interferon (IFN)-based therapy. HCV protease…
Expand
Highly Cited
2010
Highly Cited
2010
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.
J. Mccauley
,
C. J. Mcintyre
,
+19 authors
N. Liverton
Journal of medicinal chemistry
2010
Corpus ID: 42713406
A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a molecular…
Expand
Highly Cited
2010
Highly Cited
2010
Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors
A. Bae
,
Siu-Chi Sun
,
+7 authors
H. Mo
Antimicrobial Agents and Chemotherapy
2010
Corpus ID: 32756930
ABSTRACT In order to assess the natural variation in susceptibility to hepatitis C virus (HCV) NS3 protease inhibitors (PIs…
Expand
Highly Cited
2010
Highly Cited
2010
Sustained Viral Response in a Hepatitis C Virus-Infected Chimpanzee via a Combination of Direct-Acting Antiviral Agents
D. Olsen
,
M. Davies
,
+8 authors
S. Carroll
Antimicrobial Agents and Chemotherapy
2010
Corpus ID: 32416901
ABSTRACT Efforts to develop novel, interferon-sparing therapies for treatment of chronic hepatitis C (HCV) infection are…
Expand
Highly Cited
2009
Highly Cited
2009
MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease
N. Liverton
,
S. Carroll
,
+11 authors
J. Vacca
Antimicrobial Agents and Chemotherapy
2009
Corpus ID: 5904380
ABSTRACT The administration of hepatitis C virus (HCV) NS3/4A protease inhibitors to patients with chronic HCV infections has…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE